Rossi, Paolo
3 papers on CoChatORCID 0000-0002-8993-1068
Most cited papers
- Verified
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology
Botulinum Toxin and Related Neurological DisordersMultiple Sclerosis Research Studies
Cited by 475
- Verified
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Riva, N., Mora, G., Sorarù, G., Lunetta, C., Ferraro, O. E., Falzone, Y., Leocani, L., Fazio, R., Comola, M., Comi, G., et al. (2019) · The Lancet Neurology
Botulinum Toxin and Related Neurological DisordersCannabis and Cannabinoid Research
Cited by 104
- Verified
Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis
Leocani, L., Nuara, A., Houdayer, E., Schiavetti, I., Del Carro, U., Amadio, S., Straffi, L., Rossi, P., Martinelli, V., Vila, C., et al. (2015) · Journal of Neurology
Botulinum Toxin and Related Neurological DisordersCannabis and Cannabinoid Research
Cited by 66
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free